Vancomycin-resistant Enterococcus bacteremia: An evaluation of treatment with linezolid or daptomycin

Journal of Hospital Medicine

Volumn 7, Issue 3, 2012, Pages 243-248

  Twilla, Jennifer D ^a,b   Finch, Chris K ^a,b   Usery, Justin B ^a,b   Gelfand, Michael S ^a,b   Hudson, Joanna Q ^a,b   Broyles, Joyce E ^a,b  

^a METHODIST UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Antibiotics; Daptomycin; Linezolid; Vancomycin resistant Enterococcus

Indexed keywords

DAPTOMYCIN; LINEZOLID;

ADULT; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; ENTEROCOCCAL INFECTION; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; LENGTH OF STAY; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; REINFECTION; RETROSPECTIVE STUDY; TERTIARY HEALTH CARE; TREATMENT OUTCOME; TREATMENT RESPONSE; VANCOMYCIN RESISTANT ENTEROCOCCUS BACTEREMIA;

ACETAMIDES; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; DAPTOMYCIN; ENTEROCOCCUS FAECALIS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); OXAZOLIDINONES; RETROSPECTIVE STUDIES; UNITED STATES; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84857795628     PISSN: 15535592     EISSN: 15535606     Source Type: Journal    
DOI: 10.1002/jhm.994     Document Type: Article

References (25)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004; 39: 309-317.
2. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 49: 1-45.
3. Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the infectious diseases society of America. Clin Infect Dis. 2006; 42: 657-668.
4. Mave V, Garcia-Diaz J, Islam T, Hasbun R. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? J Antimicrob Chemother. 2009; 64: 175-180.
5. Arias CA, Contreras GA, Murray BE. Management of multidrug-resistant enterococcal Infections. Clin Microbiol Infect. 2010; 16: 555-562.
6. Linden PK, Moellering RC Jr, Wood CA, et al. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis. 2001; 33: 1816-1823.
7. Gallagher JC, Perez ME, Marino EA, et al. Daptomycin for vancomycin-resistant enterococcol bacteremia: a retrospective case series of 30 patients. Pharmacotherapy. 2009; 29: 792-799.
8. Smith PF, Birmingham MC, Noskin GA, et al. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant gram positive infections in cancer patients with neutropenia. Ann Oncol. 2003; 14: 795-801.
9. Kvirikadze N, Suseno M, Vescio T, Kaminer L, Singh K. Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia. Scand J Infect Dis. 2003; 38: 290-292.
10. Aksoy DY, Unal S. New antimicrobial agents for the treatment of gram positive bacterial infections. Clin Microbiol Infec. 2008; 14: 411-420.
11. Arias C, Murray BE. Emergence and management of drug-resistant enterococcal infections. Expert Rev Anti Infect Ther. 2008; 6: 637-655.
12. Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant, Vancomycin resistant Enterococcus faecium. N Engl J Med. 2002; 346: 867-869.
13. Ruggero KA, Schroeder LK, Schreckenberger PC et al. Nosocomial superinfections due to linezolid-resitant Enterococcus faecalis: evidence for a gene dosage effect of linezolid MICs. Diagn Microbiol Infect Dis. 2003; 47: 511-513.
14. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis. 2003; 36: 473-481.
15. Cubicin (Daptomycin for injection) [package insert]. Lexington, MA: Cubist Pharmaceuticals; 2010.
16. Kelesidis T, Humphries R, Uslan DZ, Pegues DA. Daptomycin nonsusceptible Enterococci: an emerging challenge for clinicians. Clin Infect Dis. 2011; 52: 228-234.
17. Canton R, Ruiz-Garbajosa P, Chaves RL, Johnson AP. A potential role for daptomycin in enterococcal infections: what is the evidence? J Antimicrob Chemother. 2010; 65: 1126-1136.
18. Crank CW, Scheetz MH, Brielmaier B, et al. Comparison of outcomes from daptomycin or linezolid for vancomycin-resistant enterococcal bloodstream infection: a retrospective, multicenter, cohort study. Clin Ther. 2010; 32: 1713-1719.
19. McKinnell JA, Patel M, Shirley RM, Kunz DF, Moser SA, Baddley JW. Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents. Epidemiol Infect. 2010; 15: 1-9.
20. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis. 2000; 31: S131-S138.
21. Vergis EN, Hayden MK, Chow JW, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia: a prospective multicenter study. Ann Intern Med. 2001; 135: 484-492.
22. D'Agata EMC, Green WK, Schulman G, Li H, Tang Y-W, Schaffner W. Vancomycin resistant enterococci among chronic hemodialysis patients: a prospective study of acquisition. Clin Infect Dis. 2001; 32: 23-29.
23. Bhavani SM, Drake JA, Forrest A, et al. A nationwide, multicenter, case control study comparing risk factors, treatment, and outcome for vancomycin resistant andsusceptible enterococcal bacteremia. Diagn Microbiol Infect Dis. 2000; 36: 145-158.
24. Kraft S, Mackler E, Schlickman P, Welch K, DePestel DD. Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients [published online ahead of print November 26, 2010]. Support Care Cancer. doi: 10.1007/s00520-010-1038-z.
25. Beezhold DW, Slaughter S, Hayden MK, et al. Skin colonization with vancomycin-resistant enterococci among hospitalized patients with bacteremia. Clin Infect Dis. 1997; 24: 704-706.